Back Hepatitis B

Hepatitis B

AASLD Liver Meeting Starts this Weekend in Boston

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting is underway, running November 9-13 at the Hynes Convention Center in Boston. The AASLD meeting each fall and the European Association for the Study of the Liver (EASL) International Liver Congress each spring are the premier events for presentation of the latest data on treatment for hepatitis B and C.alt

Read more:

Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis

Antiviral drugs including entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and tenofovir (Viread) are generally well-tolerated and effective against hepatitis B virus (HBV) in people with liver cirrhosis, and may lower mortality even among patients with severe decompensated cirrhosis, according to 2 recently published studies.alt

Read more:

Entecavir Alone Works as Well as Combo for First-time Hepatitis B Treatment

Treating chronic hepatitis B with entecavir (Baraclude) alone worked as well as dual therapy using entecavir plus tenofovir (Viread) for patients starting treatment for the first time, according to a study described in the September 2012 issue of Gastroenterology. alt

Read more:

Registry Data Show Hepatitis B Medications Appear Safe during Pregnancy

An analysis of data from the Antiretroviral Pregnancy Registry found no evidence that pregnant women's use of drugs to treat chronic hepatitis B -- including lamivudine (Epivir) and tenofovir (Viread) -- is associated with birth defects, according to a report in the November 2012 Journal of Hepatology. alt

Read more:

Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir

Tenofovir (Viread) continues to be effective for treating chronic hepatitis B patients who have developed resistance to the related drug adefovir (Hepsera), according to a report in the August 14, 2012, online edition of Antiviral Therapy.alt

Read more:

Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response

People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.alt

Read more:

Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B

While obese chronic hepatitis B patients and heavy drinkers did not have impaired virological response to entecavir (Baraclude), alcohol use did reduce the likelihood of alanine aminotransferase (ALT) normalization, according to study findings reported in the June 2012 issue of Clinical and Molecular Hepatology. alt

Read more:

Entecavir (Baraclude) Label Adds Data on Black Patients and Liver Transplant Recipients with HBV

The U.S. Food and Drug Administration this week approved revised product information for entecavir (Baraclude) for the treatment of chronic hepatitis B virus (HBV) infection, adding new data from studies of African-American patients -- showing no differences in pharmacokinetics or safety -- and of people who received liver transplants. alt

Read more:

Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents

Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.

alt

Read more: